Navigation Links
Rhode Island Governor Donald L. Carcieri and Dr. John C. Zolper, Vice President, Raytheon Company to Speak at IMAPS 2008
Date:7/28/2008

Prominent Speakers at IMAPS 2008

Washington, D.C. (PRWEB) July 28, 2008 -- The International Microelectronics and Packaging Society (IMAPS) is proud to announce that Governor Carcieri and Dr Zolper have agreed to be the Keynote Speakers at the 41st Annual International Symposium on Microelectronics (IMAPS '08) at the Providence, RI, Convention Center, November 2-6, 2008.

"IMAPS '08 is truly fortunate to have two such distinguished and knowledgeable gentlemen agree to share their insights with us at IMAPS 2008. Both Keynoters have served at the highest levels of our industries and will impart insights on the current state of our technologies on both a national and state-wide level," said Larry Rexing of Heraeus, General Chair of the IMAPS Symposium.

The Honorable Donald L. Carcieri, Governor of the State of Rhode Island, was the CEO of Cookson America and Joint Managing Director of the Cookson Group Worldwide.

Governor Carcieri joined Cookson in 1983, as President of the small start-up company. He rose through the ranks to the top position and was instrumental in the growth of the business into a major manufacturer employing over 12,000 people worldwide. The company grew from doing $30 million in sales to over $3 billion at the time of his retirement.

Governor Carcieri will speak on Wednesday, November 5. 2008.

Dr. John C. Zolper is the Vice President of Corporate Research & Development and is the Deputy for Corporate Technology and Research for Raytheon Company. Dr. Zolper is responsible for working with the Corporate Vice President of Technology and Research, on the development and execution of an integrated enterprise-wide technology and research vision and strategy. He is a participant on the Engineering & Technology Council as well as the Deputy Chair of the Technology Leadership Team.

Prior to joining Raytheon, Dr.
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
2. Turtle Island Soup Gets Souped Up with New Probiotic, GandenBC30
3. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
4. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
5. Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis New Headquarters
6. Governor Perdue Announces Georgia Selected as Home for New National Health Museum
7. Pennsylvania Governor Rendell Breaks Ground for Global Pharmaceutical Services Companys North American Headquarters
8. Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study
9. Metabolex Appoints Donald Hill as Chief Financial Officer
10. Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area
11. Vical Names Andrew de Guttadauro Vice President, Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Nikon Corporation, an innovator of advanced optical instruments, ... agreement with Harvard University granting Nikon the rights ... technology. Under the terms of the agreement, Nikon ... them with the N-STORM name. ,, Nikon ...
(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), ... their health at home through the merger of rapid diagnostics ... share on its Series B Convertible Perpetual Preferred Stock ( ... B stock in an amount per share equal to the ...
(Date:12/2/2009)... Reportlinker.com announces that a new market ... ,, Neurostimulation - A Global Market ... ,, The world neurostimulation market stands enthused ... and the resultant rise in age-related diseases ...
(Date:12/2/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... and dosimetry trial of Cotara® in patients with relapsed ... Cotara is a targeted monoclonal antibody linked to ... for GBM. Cotara specifically targets cells at the ...
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5
... an acceptable primary endpoint, for a ... 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... an agreement with the U.S. Food and Drug Administration ... registration trial of OGX-011, its lead product candidate targeting ...
... S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 ... Treatment of Epilepsy Patients With Partial Onset,Seizures , ... do Coronado, Portugal, President &,CEO Dr Luis Portela), and ... European subsidiary of Eisai Co., Ltd. (Tokyo, President &,CEO: ...
... -- Encorium Group, Inc. (Nasdaq: ... organization (CRO) that provides design, development, and management ... many of the world,s leading pharmaceutical companies, today ... Second Annual Vaccine Industry Excellence Award for Best ...
Other Biology Technology:OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 2Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 3Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 4Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 5Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 6Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 7Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 8Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 9Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 3Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 4
(Date:12/3/2009)... Now in its 32nd year, the CTRC-AACR San ... in breast cancer science and world leaders from industry ... , This year, more than 8,500 scientists and ... Convention Center in San Antonio from Dec. 9-13, 2009. ...
(Date:12/3/2009)... must be included in the design of the upcoming forest ... according to a scientist at the University of Leeds. ... argues that at least 50% of the carbon credit payments ... from Deforestation and Degredation), should be made to forest dwellers ...
(Date:12/2/2009)... cigarette smoke have an increased risk of developing lung cancer ... of this study are published in Cancer Epidemiology, Biomarkers ... Cancer Research, as part of a special tobacco focus in ... 219,000 Americans will be diagnosed with lung cancer; more than ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cystic Fibrosis Foundation Receives Second 4 Star Rating from Charity Navigator for Exceptional Fiscal Management 54308 1Cystic Fibrosis Foundation Receives Second 4 Star Rating from Charity Navigator for Exceptional Fiscal Management 54308 2New Audio Podcast Provides an Insider 26apos 3Bs View of the Healthcare System 54307 1New Audio Podcast Provides an Insider 26apos 3Bs View of the Healthcare System 54307 2New Audio Podcast Provides an Insider 26apos 3Bs View of the Healthcare System 54307 3Fountain Healthy Aging Inc Announces 245 000 000 Equity Line Of Credit Investment Secured 54304 1Fountain Healthy Aging Inc Announces 245 000 000 Equity Line Of Credit Investment Secured 54304 2Fountain Healthy Aging Inc Announces 245 000 000 Equity Line Of Credit Investment Secured 54304 3
... announced Quebec's first successful combined heart/liver transplant. The patient, ... Institut de cardiologie de Quebec (l'hôpital Laval) to the ... during a 6-hour operation on April 14, 2006 and ... 15 physicians, surgeons and other health care professionals. The ...
... new machine ?the only one of its kind in Australia ... babies. , Scientists at the Monash Institute of Medical Research ... blood pressure and the amount of oxygen in a preterm ... pressure, which reduces the oxygen supply to their brain," said ...
... particularly prone to global warming caused by industrial and ... Now, a University of Utah study finds a surprising ... Arctic's well-known haze ?made of particulate pollution from mid-latitude ... to trap heat. , The effect makes the Arctic ...
Other Biology News:MUHC announces a transplant first in Quebec 2Research offers new hope for preterm babies 2Pollutant haze heats the Arctic 2Pollutant haze heats the Arctic 3Pollutant haze heats the Arctic 4
Sheep polyclonal to Salmonella Thomasville ( Abpromise for all tested applications). Antigen: Native Salmonella thomasville...
... Rabbit polyclonal to Oct6 ( Abpromise for ... Synthetic peptide conjugated to KLH derived from within ... (Note: the amino acid sequence is proprietary) ... Entrez Gene ID: 5453 ...
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: